2013
DOI: 10.1111/bjd.12623
|View full text |Cite|
|
Sign up to set email alerts
|

The development and validation of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease

Abstract: We have shown that the TABQOL questionnaire is a valid and reliable instrument that may to be used to measure treatment burden in AIBD and serve as an end point in clinical trials.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

3
64
1
2

Year Published

2015
2015
2023
2023

Publication Types

Select...
8
1
1

Relationship

2
8

Authors

Journals

citations
Cited by 65 publications
(70 citation statements)
references
References 22 publications
3
64
1
2
Order By: Relevance
“…Mucocutaneous disease has significant impacts on the QoL of patients which may not be reflected on disease activity scoring systems. The autoimmune bullous disease QoL (ABQOL) and treatment of autoimmune bullous disease QoL (TABQOL) are validated tools which identify the impact the disease has on the patient's daily activities, work and relationships as well as the cost of medication, burden of taking the medication and anxiety about the underlying disease …”
Section: Quality Of Life (Qol) Measures In Aibdmentioning
confidence: 99%
“…Mucocutaneous disease has significant impacts on the QoL of patients which may not be reflected on disease activity scoring systems. The autoimmune bullous disease QoL (ABQOL) and treatment of autoimmune bullous disease QoL (TABQOL) are validated tools which identify the impact the disease has on the patient's daily activities, work and relationships as well as the cost of medication, burden of taking the medication and anxiety about the underlying disease …”
Section: Quality Of Life (Qol) Measures In Aibdmentioning
confidence: 99%
“…In some studies, oral-health generic QOL measures such as Chronic Oral Mucosal Diseases Questionnaire (COMDQ) or psychiatric generic measures such as the 12-item General Health Questionnaire (GHQ-12) have also been used. However, none of those measures were disease-specific until the development of the Autoimmune Bullous Disease Quality of Life (ABQOL) questionnaire and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaire by the Murrell group (Sebaratnam et al, 2013, Tjokrowidjaja et al, 2013). The ABQOL and TABQOL have both been shown as valid and reliable instruments for measuring QOL and treatment burden, respectively, in AIBDs.…”
Section: Quality Of Lifementioning
confidence: 99%
“…The ABQOL is more sensitive compared to the DLQI due to its higher content validity . The Treatment of Autoimmune Bullous Disease Quality of Life questionnaire (TABQOL) was developed from the pilot ABQOL questionnaire and assesses the impact of treatment on QoL …”
Section: Introductionmentioning
confidence: 99%